Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
Innovent Biologics (HKEX: 01801) announced that its drug SYCUME® (Teprotumumab N01 Injection) met its primary endpoint in a Phase 3 trial for inactive thyroid eye disease (TED). The study showed a 60.4% response rate and a -1.88 mm reduction in proptosis at Week 24, with a favorable safety profile. SYCUME® is the first IGF-1R antibody drug in China and the second approved worldwide, included in China's National Reimbursement Drug List.
How this was made
The 30-second read
Why it matters
The trial data could accelerate commercial launch and drive revenue growth.
Market read
First positive Phase 3 data for an IGF-1R antibody in China, likely to move the stock and sector.
What to watch
Potential competition from other IGF-1R antibodies and regulatory timelines in other markets.
Background
Innovent Biologics is a Chinese biopharma with a portfolio spanning oncology, autoimmune, and ophthalmology.
Market effects
Strengthens the biotech sector's outlook on ophthalmology and autoimmune therapies.
May lift sentiment for Hong Kong-listed biotech stocks.
Adds to global pipeline of IGF-1R antibodies, could influence peer valuations.
Counterpoint
Skeptics may question long-term safety and reimbursement sustainability.
Key entities
- companyInnovent Biologics
Developer of SYCUME® (Teprotumumab).
- drugSYCUME® (Teprotumumab)
IGF-1R antibody for thyroid eye disease.
